New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
09:31 EDTKOCoca-Cola names Julie Hamilton as Chief Customer & Commercial Leadership Officer
Subscribe for More Information
07:20 EDTJNJGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
17:16 EDTKOCoca-Cola sees FY15 comparable currency neutral EPS growth similar to FY14
Subscribe for More Information
16:27 EDTKOCoca-Cola sees 2015 net share repurchases of $2B-$3B
As previously indicated, the company does not expect comparable currency neutral EPS growth in 2015 to be significantly different from 2014. Longer term, the company intends to return to delivering against its stated growth targets. Based on current spot rates, existing hedge positions, and the cycling of 2014 rates, the company now expects a 5 to 6 point currency headwind on profit before tax in 2015. The underlying effective annual tax rate on operations in 2015 is currently expected to be 22.5%. In 2015, the company is targeting net share repurchases of $2B to $3B.
16:25 EDTKOCoca-Cola sees 9 point currency headwind on Q4 EPS
Subscribe for More Information
16:20 EDTKOCoca-Cola sees FY14 comparable currency neutral EPS growth of 4%-5%
Subscribe for More Information
16:00 EDTKOOptions Update; December 15, 2014
Subscribe for More Information
13:52 EDTKOWintergreen says Coca-Cola CEO Muhtar Kent 'incapable' of leading turnaround
Subscribe for More Information
06:37 EDTSCHWCharles Schwab files automatic mixed securities shelf
Subscribe for More Information
December 12, 2014
14:01 EDTJNJGenOn Energy to receive $3M milestone payment in Janssen collaboration
Genmab announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech (JNJ), triggering a $3M payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Today's news will not impact Genmab's 2014 financial guidance.
08:46 EDTSCHWCharles Schwab reports November net new assets $10.9B
Subscribe for More Information
December 10, 2014
10:00 EDTKOCoca-Cola to host conference call
Conference call to address financial and modeling-related questions will be held on December 15 at 4:30 pm. Webcast Link
07:14 EDTCNSIComverse reports Q3 EPS 4c, consensus (21c)
Subscribe for More Information
December 9, 2014
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
16:36 EDTPBYPep Boys says has engaged Spencer Stuart to conduct CEO search
Subscribe for More Information
16:35 EDTPBYPep Boys reports Q3 EPS (3c) with items, consensus 12c
Subscribe for More Information
16:22 EDTKOCoca-Cola Bottling in pact with Coca-Cola to expand franchise territory
Subscribe for More Information
15:20 EDTPBYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include AutoZone(AZO), consensus $7.16; HD Supply (HDS), consensus 53c; Burlington Stores (BURL), consensus 12c; Science Applications International (SAIC), consensus 74c; UTi Worldwide (UTIW), consensus 6c; The Pantry (PTRY), consensus 46c; Pep Boys (PBY), consensus 12c.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use